PhRMA and Community Oncology Alliance submitted comments to the FTC criticizing 340B contract pharmacies in response to the commission’s call for public input on PBMs’ business practices.

PhRMA and Private Oncology Practices Slam PBMs’ Role in 340B in Comments to FTC

Drug makers and independent oncology practices slammed pharmacy benefit managers’ role in 340B contract pharmacy growth in recent public comment to the Federal Trade Commission.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

*Sign up for news summaries and alerts from 340B Report